Nice Quarter from A...
Health Care: Drugs
Dyax Corporation (DYAX: NASDAQ)
$1.49 -0.07 | -4.49%
02/09/12 - 03:15 PM ET
122.66K / 378.80K
Vol / Avg. Vol:1.57 / 1.56
Open / Prev. Close:1.49 - 1.58
Today's Range:1.10 - 2.33
52 Wk Range:14.71%
Performance YTD:TheStreet Rating:
Portfolios with DYAX
- Portfolio NameUser Type
- UserSUPRATRADE-0303071618
- Userdulcinea
- ContributorOptions Action Portfolio Fe...
- UserLast Day of the JPMorgan He...
- UserBarron's Research Reports 7...
- UserPART 6 JPMorgan 26th Annual...
- Userpnp.v
- UserSpec #1
- Userjan's specs
- Userslarsen Portfolio 1
Latest DYAX Headlines from TheStreet
- Dyax Stock Gaps Down On Today's Open (DYAX) 07.19.11 | 09:07 am
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 03:10 am
- Dyax Corp. Q2 2010 Earnings Call Transcript 07.28.10 | 10:07 pm
- Merck Buys British Maker Of Biotech Medicines 12.17.09 | 12:12 pm
- Cubist Stops Enrollment In Anti-bleeding Studies 12.03.09 | 01:12 pm
- Delta, Walgreen, Diedrich Coffee Are Big Movers 12.02.09 | 04:12 pm
- Dyax Shares Rocket On FDA Clearance For Kalbitor 12.02.09 | 11:12 am
- Dyax, RF Micro: Early Volume Plays 12.02.09 | 08:12 am
- FDA Approves Two New Drugs: BioBuzz 12.02.09 | 07:12 am
- Dyax Gets FDA Approval For Genetic Disorder Drug 12.01.09 | 07:12 pm
Press Releases for DYAX
- Dyax Corp. Enters Into New Loan Agreement With Cowen Healthcare Royalty Partners - Business Wire 01.04.12 | 07:01 am
- Dyax Corp. Provides Update On International Regulatory Status Of KALBITOR® (ecallantide) - Business Wire 11.14.11 | 07:11 am
- KALBITOR® (ecallantide) Data In HAE Presented At The American College Of Allergy, Asthma And Immunology Annual Meeting - Business Wire 11.07.11 | 07:11 am
- Dyax Corp. Appoints Ron Cohen, M.D. And Paolo Pucci To Board Of Directors - Business Wire 11.01.11 | 07:11 am
- Dyax Corp. Announces Third Quarter 2011 Financial Results - Business Wire 10.27.11 | 04:10 pm
- Dyax Corp. To Host Third Quarter 2011 Earnings Call And Webcast - Business Wire 10.20.11 | 07:10 pm
- Dyax Corp. To Present At September 2011 Investor Conferences - Business Wire 09.06.11 | 07:09 pm
- Dyax Announces Treatment Of First Patient In Phase 2 Trial Of Ecallantide For Acute Treatment Of ACE Inhibitor-Induced Angioedema - Business Wire 08.04.11 | 07:08 am
- Dyax Corp. Announces Second Quarter 2011 Financial Results - Business Wire 07.27.11 | 04:07 pm
- Dyax Corp. And Kadmon Corporation Announce Antibody Library License Agreement - Business Wire 07.26.11 | 07:07 am
Partner Headlines for DYAX
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Dyax Corp. Hits New 52-Week Low (DYAX) - Benzinga 01.04.11 | 09:01 am
- UPDATE 1-Dyax, Sigma-Tau agree to develop, market genetic drug - Reuters 06.21.10 | 08:06 am
- CORRECTED - CORRECTED-UPDATE 1-Dyax posts narrower-than-expected Q4 loss - Reuters 02.17.10 | 09:02 am
